Open an account

USANA Health Sciences

USNA · NYSE

$14.72−$0.17 (−1.14%)TodayMarket closed ·
Prev close $14.89

About USNA

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. The company is headquartered in Salt Lake City, Utah and currently employs 1,570 full-time employees. Its segments include Direct selling and Hiya direct-to-consumer. The Direct Selling segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children’s health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, and Foods. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. Essentials/CellSentials products include USANA CellSentials and HealthPak 100.

Employees
1,570
Headquarters
Salt Lake City, Utah
Listed
Oct 28, 1993
Sector
Consumer Staples
Industry
Personal Care Products
Website
usana.com

USNA key statistics

Market cap
275.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
172.02K
Volume
125.76K
Open price
$15.00
High today
$15.63
Low today
$14.65
52 Week high
$23.59
52 Week low
$12.57

USANA Health Sciences (USNA) at a glance

USANA Health Sciences (USNA) last traded at $14.72, with a market cap of 275.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $14.65 and $15.63. The current price is 0.4% above the day's low and 5.8% below its high.

Volume so far is 125.76K shares, below the average of 172.02K shares a day.

Over the past year USANA Health Sciences has ranged from $12.57 to $23.59, and now sits 20% of the way up that range.

USANA Health Sciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of $0.4386.

USNA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 26.2% on average.

  1. Q3 FY24: reported $0.56 per share against an estimate of $0.4947
  2. Q4 FY24: reported $0.64 per share against an estimate of $0.4993
  3. Q1 FY25: reported $0.73 per share against an estimate of $0.714
  4. Q2 FY25: reported $0.74 per share against an estimate of $0.5508
  5. Q3 FY25: reported -$0.15 per share against an estimate of $0.4794
  6. Q4 FY25: reported $0.60 per share against an estimate of $0.4182
  7. Q1 FY26: reported $0.61 per share against an estimate of $0.4488
  8. Q2 FY26: reported -$0.07 per share against an estimate of $0.4386

USNA news

  • Press releaseBusiness Wire

    USANA Schedules Third Quarter 2026 Earnings Release and Conference Call

  • Press releasePRNewswire

    USANA Health Sciences and University of Utah Athletics Announce New Partnership

  • Press releasePRNewswire

    USANA CEO Kevin Guest Shares Three Ways to Celebrate International Music Day

  • Press releasePRNewswire

    Protein Pop Launches Protein Pop Balance, a Clear Prebiotic Soda with 15 Grams of Protein and 5 Grams of Fiber

  • Press releasePRNewswire

    USANA CEO Kevin Guest Calls on People to Find a Way to Serve Others, Then Act

  • Press releasePRNewswire

    USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix

  • Press releasePRNewswire

    USANA Chairman, CEO Kevin Guest Shares 5 Ways to Make Happiness Happen at Work and Home This August

  • Press releaseBusiness Wire

    USANA Health Sciences Reports Second Quarter 2026 Results

Similar companies

Companies in the same industry as USANA Health Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.